What's Happening?
DexCom, Inc. has announced the results of the CONNECT randomized controlled trial, which demonstrates significant benefits of using the Dexcom G7 continuous glucose monitoring (CGM) system for people with Type 2 diabetes not using insulin. The study,
presented at the 2026 Scientific Sessions of the American Diabetes Association, showed that the use of Dexcom G7 led to a clinically and statistically significant reduction in HbA1c levels and improved glucose control compared to routine care. The trial involved 283 participants across the United States, with results indicating a 1.6% average reduction in HbA1c for those using the Dexcom G7. The study highlights the potential of CGM systems to become a new standard of care for managing Type 2 diabetes.
Why It's Important?
The findings from the CONNECT study are significant as they provide level A evidence, the highest level of evidence graded by the American Diabetes Association, supporting the use of CGM systems for Type 2 diabetes patients not on insulin. This could lead to a shift in diabetes management practices, offering a more effective way to monitor and control blood glucose levels. The study's results may influence healthcare policies and insurance coverage, making CGM systems more accessible to a broader population. The potential for improved patient outcomes and reduced healthcare costs makes this development particularly impactful for the healthcare industry.
What's Next?
A six-month extension phase of the CONNECT trial is underway to assess the long-term benefits of the Dexcom G7 system. The results of this extension could further solidify the role of CGM systems in diabetes management. Additionally, the study's findings may prompt healthcare providers to consider integrating CGM systems into standard care protocols for Type 2 diabetes patients. As the healthcare industry adapts to these advancements, there may be increased demand for CGM technology, leading to further innovations and improvements in diabetes care.
